These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

722 related items for PubMed ID: 22712620

  • 1. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy.
    Harada K, Miyake H, Kusuda Y, Fujisawa M.
    BJU Int; 2012 Dec; 110(11 Pt C):E1131-7. PubMed ID: 22712620
    [Abstract] [Full Text] [Related]

  • 2. Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy.
    Sakai I, Miyake H, Takenaka A, Fujisawa M.
    BJU Int; 2009 Oct; 104(7):942-6. PubMed ID: 19388989
    [Abstract] [Full Text] [Related]

  • 3. Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy.
    Behnsawy HM, Miyake H, Harada K, Fujisawa M.
    BJU Int; 2013 Jan; 111(1):30-7. PubMed ID: 23107154
    [Abstract] [Full Text] [Related]

  • 4. NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy.
    Liang ZL, Kang K, Yoon S, Huang SM, Lim JS, Kim JM, Lim JS, Lee HJ.
    Ann Surg Oncol; 2012 Aug; 19(8):2763-72. PubMed ID: 22246425
    [Abstract] [Full Text] [Related]

  • 5. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
    Kusuda Y, Miyake H, Behnsawy HM, Fukuhara T, Inoue TA, Fujisawa M.
    Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
    [Abstract] [Full Text] [Related]

  • 6. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
    Nishikawa M, Miyake H, Harada K, Fujisawa M.
    Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
    [Abstract] [Full Text] [Related]

  • 7. Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection.
    Liu B, Miyake H, Nishikawa M, Fujisawa M.
    Urol Oncol; 2015 Mar; 33(3):110.e11-8. PubMed ID: 25262382
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dysregulation of β-catenin is an independent predictor of oncologic outcomes in patients with clear cell renal cell carcinoma.
    Krabbe LM, Westerman ME, Bagrodia A, Gayed BA, Darwish OM, Haddad AQ, Khalil D, Kapur P, Sagalowsky AI, Lotan Y, Margulis V.
    J Urol; 2014 Jun; 191(6):1671-7. PubMed ID: 24291548
    [Abstract] [Full Text] [Related]

  • 10. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis.
    Park YH, Baik KD, Lee YJ, Ku JH, Kim HH, Kwak C.
    BJU Int; 2012 Dec; 110(11 Pt B):E553-8. PubMed ID: 22578274
    [Abstract] [Full Text] [Related]

  • 11. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, Cunico SC, Longo N, Martignoni G, Minervini A, Mirone V, Simonato A, Terrone C, Zattoni F, Ficarra V, Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project, Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation.
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [Abstract] [Full Text] [Related]

  • 12. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
    Jorns J, Thiel DD, Lohse CM, Williams A, Arnold ML, Cheville JC, Leibovich BC, Parker AS.
    BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
    [Abstract] [Full Text] [Related]

  • 13. Microscopic venous invasion in renal cell carcinoma as a predictor of recurrence after radical surgery.
    Ishimura T, Sakai I, Hara I, Eto H, Miyake H.
    Int J Urol; 2004 May; 11(5):264-8. PubMed ID: 15147540
    [Abstract] [Full Text] [Related]

  • 14. Long-term outcome of small, organ-confined renal cell carcinoma (RCC) is not always favourable.
    Shindo T, Masumori N, Kobayashi K, Fukuta F, Hirobe M, Tonooka A, Hasegawa T, Kitamura H, Tsukamoto T.
    BJU Int; 2013 May; 111(6):941-5. PubMed ID: 23350965
    [Abstract] [Full Text] [Related]

  • 15. Clinicopathological features of recurrence after radical surgery for nonmetastatic renal cell carcinoma.
    Ishimura T, Sakai I, Harada K, Hara I, Eto H, Miyake H.
    Int J Clin Oncol; 2004 Oct; 9(5):369-72. PubMed ID: 15549586
    [Abstract] [Full Text] [Related]

  • 16. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma.
    Komai Y, Saito K, Sakai K, Morimoto S.
    BJU Int; 2007 Jan; 99(1):77-80. PubMed ID: 16956357
    [Abstract] [Full Text] [Related]

  • 17. Expression profile of E-cadherin and N-cadherin in urothelial carcinoma of the upper urinary tract is associated with disease recurrence in patients undergoing nephroureterectomy.
    Muramaki M, Miyake H, Terakawa T, Kusuda Y, Fujisawa M.
    Urology; 2011 Dec; 78(6):1443.e7-12. PubMed ID: 21924460
    [Abstract] [Full Text] [Related]

  • 18. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M.
    Urol Oncol; 2010 Dec; 28(2):145-51. PubMed ID: 18848789
    [Abstract] [Full Text] [Related]

  • 19. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension.
    Kurahashi T, Muramaki M, Yamanaka K, Hara I, Miyake H.
    BJU Int; 2005 Oct; 96(6):895-9. PubMed ID: 16153225
    [Abstract] [Full Text] [Related]

  • 20. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma.
    Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A, Pantuck AJ.
    J Urol; 2005 Mar; 173(3):725-8. PubMed ID: 15711252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.